

<u>MA (EU) number</u>	<u>(Invented) name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of Administration</u>	<u>Immediate Packaging</u>	<u>Content (concentration)</u>	<u>Pack size</u>
EU/1/10/614/002	Menveo	--1	Powder and solution for solution for injection	Intramuscular use	MenA lyophilised conjugate component: vial (glass); MenCWY liquid conjugate component: vial (glass)	0.5 ml	5 vials + 5 vials
EU/1/10/614/003	Menveo	--1	Powder and solution for solution for injection	Intramuscular use	MenA lyophilised conjugate component: vial (glass); MenCWY liquid conjugate component: vial (glass)	0.5 ml	1 vial + 1 vial
EU/1/10/614/004	Menveo	--1	Powder and solution for solution for injection	Intramuscular use	MenA lyophilised conjugate component: vial (glass); MenCWY liquid conjugate component: vial (glass)	0.5 ml	10 vials + 10 vials
EU/1/10/614/005	Menveo	--1	Solution for injection	Intramuscular use	vial (glass)	0.5 ml	1 vial
EU/1/10/614/006	Menveo	--1	Solution for injection	Intramuscular use	vial (glass)	0.5 ml	10 vials

--1

One dose (0.5ml) contains:

Meningococcal group A oligosaccharide 10 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 16.7 to 33.3 micrograms

Meningococcal group C oligosaccharide 5 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 7.1 to 12.5 micrograms

Meningococcal group W135 oligosaccharide 5 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 3.3 to 8.3 micrograms

Meningococcal group Y oligosaccharide 5 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 5.6 to 10.0 micrograms